Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $254.50.
A number of analysts recently weighed in on CRL shares. Mizuho began coverage on shares of Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 price target for the company. TD Cowen dropped their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a research note on Monday, May 13th. The Goldman Sachs Group initiated coverage on shares of Charles River Laboratories International in a report on Thursday, June 6th. They issued a “buy” rating and a $290.00 target price on the stock. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a report on Friday. Finally, StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, June 14th.
View Our Latest Report on Charles River Laboratories International
Insider Buying and Selling at Charles River Laboratories International
Institutional Trading of Charles River Laboratories International
A number of hedge funds have recently bought and sold shares of the company. VisionPoint Advisory Group LLC grew its position in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $41,000. Operose Advisors LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $42,000. Brown Brothers Harriman & Co. lifted its holdings in shares of Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at $62,000. Institutional investors and hedge funds own 98.91% of the company’s stock.
Charles River Laboratories International Price Performance
Shares of CRL opened at $206.58 on Thursday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. Charles River Laboratories International has a 1-year low of $161.65 and a 1-year high of $275.00. The stock has a market cap of $10.64 billion, a PE ratio of 24.30, a price-to-earnings-growth ratio of 1.96 and a beta of 1.40. The firm has a fifty day moving average price of $220.16 and a 200 day moving average price of $232.63.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. As a group, sell-side analysts anticipate that Charles River Laboratories International will post 11 EPS for the current year.
About Charles River Laboratories International
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- What is the Shanghai Stock Exchange Composite Index?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the Dow Jones Industrial Average (DJIA)?
- MarketBeat Week in Review – 6/24 – 6/28
- How to Use the MarketBeat Stock Screener
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.